Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712810 · ClinicalTrials.gov registry record · Phase 1
Q702 for the Treatment of Patients With Hematologic Malignancies
A Phase 1 study of Hematopoietic and Lymphatic System Neoplasm and Recurrent Chronic Lymphocytic Leukemia, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 2
- Study locations
NCT06712810 is a Phase 1 study of Hematopoietic and Lymphatic System Neoplasm and Recurrent Chronic Lymphocytic Leukemia that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 46 participants, below the 482-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06712810, a Phase 1 study of Hematopoietic and Lymphatic System Neoplasm and Recurrent Chronic Lymphocytic Leukemia, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Aspiration
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Computed Tomography
- DRUG Axl/Mer/CSF1R Inhibitor Q702
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-08-27 |
| Est. Completion | 2030-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06712810
The ClinicalTrials.gov registry entry for NCT06712810 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (90% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Hematopoietic and Lymphatic System Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06712810 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06712810 about?
NCT06712810 is a clinical study titled "Q702 for the Treatment of Patients With Hematologic Malignancies". This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal bloo...
What is the current status of trial NCT06712810?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2025-08-27. Estimated completion is 2030-09-15.
What conditions does trial NCT06712810 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphatic System Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT06712810?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Axl/Mer/CSF1R Inhibitor Q702 (DRUG).
Who is sponsoring clinical trial NCT06712810?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712810 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphatic System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
RECRUITING · Phase 1
-
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
RECRUITING
-
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
RECRUITING
-
Voices: Messages of Wisdom and Hope in the Face of Illness
RECRUITING
-
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RECRUITING
Explore more on PlainTrial
Hematopoietic and Lymphatic System Neoplasm
All registered trials for this condition
Recurrent Chronic Lymphocytic Leukemia
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.